Shreyansh Singh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shreyansh Singh has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Avijit Mazumder
Department of Pharmacology, Noida Institute of Engineering and Technology (Pharmacy Institute), Knowledge Park-II, Greater Noida, 201306 Uttar Pradesh, India
1 shared publication - Monika Monika
Noida Institute of Engineering and Technology (Pharmacy Institute)
1 shared publication - Rupa Mazumder
Department of Pharmaceutics, Noida Institute of Engineering and Technology (Pharmacy Institute), Greater Noida, India
1 shared publication
Latest Publications
- 30 September 2026
- Published by Bentham Science Publishers Ltd. in Current Chemical Biology
- Vol. 20, 1-17
Stimuli-Responsive Therapeutics for Anxiety Management
Introduction: Anxiety disorders have neurochemical imbalances, structural changes in the brain, and dysfunctional neurotransmitter systems. The challenge in treating these disorders is the complexity of the Blood-Brain Barrier (BBB) and the ineffectiveness of traditional pharmacological methods, which may not provide accurate targeting of drugs and could be toxic. Methodology: The literature study was performed to identify relevant studies on Stimuli-Responsive Drug Delivery Systems (SRDDS) and their uses in the treatment of anxiety. The major databases, including PubMed, Scopus, Web of Science, and Google Scholar, were thoroughly studied. Results: SRDDS had great potential in improving bioavailability, achieving targeted release, and reducing systemic side effects in the treatment of anxiety disorders. Responsive systems to internal and external stimuli helped improve drug penetration through the BBB and prolonged the effects. Discussion: The incorporation of SRDDS in the treatment of anxiety fills a major gap in the conventional delivery of drugs by ensuring a controlled release at the desired site. Although the interdisciplinary approach of nanotechnology, materials science, and neurobiology has helped advance the field, concerns about cost, reproducibility, and safety remain. Conclusion: SRDDS offers a new approach to managing anxiety by allowing for targeted, controlled, and flexible delivery of anxiolytics through the BBB. While most existing evidence is still at the preclinical level, ongoing investigations, the incorporation of biomarkers, and improvements in scalable manufacturing techniques could help turn these systems into effective, customized treatments for anxiety disorders.
- 30 September 2026
- Published by Bentham Science Publishers Ltd. in Current Chemical Biology
- Vol. 20, 1-17
Stimuli-Responsive Therapeutics for Anxiety Management
Introduction: Anxiety disorders have neurochemical imbalances, structural changes in the brain, and dysfunctional neurotransmitter systems. The challenge in treating these disorders is the complexity of the Blood-Brain Barrier (BBB) and the ineffectiveness of traditional pharmacological methods, which may not provide accurate targeting of drugs and could be toxic. Methodology: The literature study was performed to identify relevant studies on Stimuli-Responsive Drug Delivery Systems (SRDDS) and their uses in the treatment of anxiety. The major databases, including PubMed, Scopus, Web of Science, and Google Scholar, were thoroughly studied. Results: SRDDS had great potential in improving bioavailability, achieving targeted release, and reducing systemic side effects in the treatment of anxiety disorders. Responsive systems to internal and external stimuli helped improve drug penetration through the BBB and prolonged the effects. Discussion: The incorporation of SRDDS in the treatment of anxiety fills a major gap in the conventional delivery of drugs by ensuring a controlled release at the desired site. Although the interdisciplinary approach of nanotechnology, materials science, and neurobiology has helped advance the field, concerns about cost, reproducibility, and safety remain. Conclusion: SRDDS offers a new approach to managing anxiety by allowing for targeted, controlled, and flexible delivery of anxiolytics through the BBB. While most existing evidence is still at the preclinical level, ongoing investigations, the incorporation of biomarkers, and improvements in scalable manufacturing techniques could help turn these systems into effective, customized treatments for anxiety disorders.